A Single-arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Lenvatinib (Primary) ; Everolimus
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 15 Feb 2018 Trial design presented at the 32nd Congress of the European Association of Urology.
- 24 Feb 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2018.
- 24 Feb 2017 Status changed from not yet recruiting to recruiting.